The Barostim neo System is an implantable neuromodulation device designed to improve cardiac function by delivering electrical stimulation to baroreceptors in the wall of the carotid artery. The system is designed to take advantage of the body’s natural baroreflex system. Activation of baroreceptors in the wall of the carotid artery with baroreflex activation therapy stimulates pathways of the autonomic nervous system, resulting in decreased arterial resistance and decreased afterload on the heart, thereby alleviating symptoms of heart failure. The Barostim neo System is indicated for the improvement of symptoms in patients with New York Heart Association (NYHA) Class II/III heart failure (with a recent history of Class III) who remain symptomatic despite optimal medical therapy; have an ejection fraction of 35% or less; and are not candidates for cardiac resynchronization therapy (CRT).

If you have a Hayes login, click here to view the full report on the Knowledge Center.